China
Africa
Explore chapters and articles related to this topic
Herbal and Supplement Use in Pain Management
Published in Sahar Swidan, Matthew Bennett, Advanced Therapeutics in Pain Medicine, 2020
Dose:Fibromyalgia: preliminary clinical research suggests that taking cholecalciferol reduces the pain that fibromyalgia patients experience.121 The greatest effects were in patients who also had low serum levels of vitamin D compared with that of placebo. Quality of life was not affected.121 The dose depended on the patient’s plasma vitamin D status, with patients taking 2400 IU daily if calcifediol levels were <60 nmol/L or 1200 IU daily if serum calcifediol were 60–80 nmol/L at baseline. Supplementation was conducted to achieve and maintain blood levels between 32 and 48 ng/mL for 20 weeks.121
Fat-Soluble Vitamins
Published in Luke R. Bucci, Nutrition Applied to Injury Rehabilitation and Sports Medicine, 2020
Vitamin D therapy is in use for osteomalacia and rickets. Large doses of 10,000 to 300,000 IU daily of cholecalciferol have been used.497 However, increasing use is being made of 1,25OHD at small oral doses with equivalent results. Prevention of steroid-induced osteopenia may be prevented by large doses of vitamin D2, but results have not been replicated.502 A link between vitamin D metabolism and osteoporosis is still being explored. This has ramifications for amenorrheic female athletes with bone loss. At this time, it is unknown if vitamin D supplements would aid in repletion of bone mass in amenorrheic athletes. Likewise, the effects of vitamin D supplements on fracture healing in humans are not fully known. Topical application of 5 ng per wound per day of 1,25OHD to skin punch biopsies in rats led to significant acceleration of wound closure, accomplished in the first 2 d postwounding.504
Alternatives to hormone replacement therapy: what is the role of calcium and vitamin D?
Published in Barry G. Wren, Progress in the Management of the Menopause, 2020
Cholecalciferol has no significant preventive or therapeutic effect in vitamin D-replete postmenopausal women. Since vitamin D deficiency increases with advancing age, cholecalciferol supplements in combination with calcium are very effective, however, in later life, in reducing secondary hyperpara-thyroidism, bone loss and fracture incidence.
Vitamin D and COVID-19: where are we now?
Published in Postgraduate Medicine, 2023
Victoria Contreras-Bolívar, Beatriz García-Fontana, Cristina García-Fontana, Manuel Muñoz-Torres
An update was published by the National Institute for Health and Care Excellence (NICE): ‘COVID-19 rapid guideline: vitamin D’ that recommended vitamin D supplementation for people in confined spaces, those living in residences, with low sun exposure, or spending more time at home due to the COVID-19 pandemic [124]. The recommended dose is 400 IU/day of cholecalciferol. The recommended period is between October and March (indicated all year round for people without sun exposure during spring and summer). The objective proposed by the authors was to achieve levels of 25(OH)D3 > 10 ng/mL to maintain optimal bone health. The authors indicated that low 25(OH)D3 levels are associated with more severe COVID-19 outcomes. However, they also cautioned that vitamin D supplementation should not be administered solely for the purpose of preventing or treating COVID-19, as clinical trials are necessary to give this recommendation. The US National Academy of Medicine and the European Food Safety Authority recommend achieving 25(OH)D3 levels at least 20 ng/mL. For this purpose, it was indicated that supplementation should be done at 800 IU/day. In addition, in the case of hospital admissions, it is recommended that 25(OH)D3 levels be determined on admission [125].
Cholecalciferol complexation with hydroxypropyl-β-cyclodextrin (HPBCD) and its molecular dynamics simulation
Published in Pharmaceutical Development and Technology, 2022
Fang Wang, Wenbo Yu, Carmen Popescu, Ahmed Ashour Ibrahim, Dongyue Yu, Ryan Pearson, Alexander D. MacKerell, Stephen W. Hoag
For these studies, the goal was to improve the aqueous solubility of cholecalciferol. HPBCD is added as a solubilizing excipient. The complexation mechanism between cholecalciferol and HPBCD was evaluated experimental and by computer simulation revealing a rare type AP complexation behavior (Takeru and Kenneth 1965; Phennapha et al. 2018) through both methods. Cholecalciferol is wildly used in many clinical research studies, and IV administration can lead to a faster collection of biological data compared to other dosage like oral dose forms. Worth mentioning that at present time there is no related literature data on liquid based parenteral cholecalciferol formulation. We developed a new parenteral cholecalciferol formulation based on its complexation with HPBCD (with a molar substitution (MS) of 0.58–0.68). In preliminary studies, the complex liquid formulations data of 6-months stability demonstrated that high concentration HPBCD could preserve cholecalciferol, but could not keep it stable in the liquid formulation for long time storage. To increase cholecalciferol–HPBCD complex stability, spray-dried dispersions (SDDs) were made as dry powder. It would be used as reconstitutable powder for injection using sterile water. Complex formation and its amorphous character in SDDs was validated by DSC and concurrently by FTIR, XRD and illustrated by SEM. Meanwhile, molecular dynamics (MD) simulation evaluation is based on 1:1 complexation interaction between cholecalciferol and HPBCD.
The effect of vitamin D supplementation in treatment of children with autism spectrum disorder: a systematic review and meta-analysis of randomized controlled trials
Published in Nutritional Neuroscience, 2022
Bingbing Li, Yiran Xu, Xiaoli Zhang, Lingling Zhang, Yanan Wu, Xiaoyang Wang, Changlian Zhu
Table 1 summarizes the characteristics of the included studies. Among them, two studies were conducted in New Zealand12,17, one in Egypt18, one in Iran19 and one in Ireland13. All five studies were published in English between 2014 and 2019, and the five selected trials recruited 349 participants aged 2–12 years diagnosed with ASD (309 were male and 40 were female). Vitamin D supplementation was in the form of cholecalciferol in all five RCTs. For the intervention group, the daily doses were 2,000 IU/day in four RCTs, and the remaining study used 300 IU/kg/day not to exceed 5,000 IU/day19. All included studies except one were placebo-controlled. All studies included both males and females, except for the Moradi, 2018, study19 that only included males. The male to female ratio ranged from 3/1–7/1. The interventions lasted 3 months (one RCT), 5 months (one RCT), 6 months (one RCT), and 12 months (two RCTs).